Astrazeneca in the terminal: up to $ 8 million punishment in China!

Astrazeneca in the terminal: up to $ 8 million punishment in China!

astrazeneca is faced with considerable challenges in China, including an impending fine of up to $ 8 million ($ 7 million). This punishment could be imposed because the company has probably not paid imports. Authorities in Shenzhen have estimated the outstanding amounts to around $ 1.6 million. If Astrazeneca found guilty, the punishment between the income and five times could be a significant increase, which would significantly increase the possible burden. The allegations refer to the breast cancer in particular enachu reports OE24

In addition, similar problems were also uncovered in connection with the IMFINZI and IMJUDO cancer medication, and for which AstraZeneca must already expect a penalty of up to $ 4.5 million. In February 2023, the corporate management announced that the investigation in the matter could possibly be extended to Enertu. Astrazenecca also assured cooperation with the Chinese authorities to clarify tax matters.

political pressure and corporate engagement

Political pressure on Astrazeneca has increased in the past few months. Last year, the then China boss Leon Wang came into the focus of the investigation and was arrested by the Chinese authorities. This led the company to appoint a new president for his operations in China. These developments not only result in administrative upheaval, but also challenges in international business. For example, President Trump has exerted pressure on US pharmaceutical companies to move their production facilities to the USA.

The total revenue of AstraZeneca in 2024 grew by impressive 18 percent to £ 43.3 billion, whereby sales increase 24 percent with oncology medication. This success underlines the company's intention to invest even more in the coming years, especially in research and development. CEO Pascal Soriot mentioned that AstraZeneca had the goal of reaching $ 80 billion overall sales by the end of the decade an .

investments in China

Regardless of the current challenges, Astrazeneca plans a massive total investment of over $ 10 billion in China to establish a new global strategic center. An investment of $ 2.5 billion is planned over five years in Beijing, with the aim of building a sixth global research and development center. This center will concentrate on early studies, clinical developments and partnerships with companies in the field of biotechnology and artificial intelligence So Biospace .

In addition, AstraZeneca will work with various partners to develop innovative treatments. These include agreements with Harbor Biomed and Syneron Bio. Ultimately, the company aims to strengthen its position on the important Chinese market, even though it is facing political and financial challenges at the same time.